Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Sponsor

Jiangsu Hengrui Pharmaceuticals Co. Ltd.

7 Kunlunshan Road, Economic And Technological Development Zone, 222047

About the sponsor

Research activity includes treatment strategies for metastatic hormone-sensitive prostate cancer with high tumor load and metastatic castration-resistant prostate cancer, with attention to disease control and progression outcomes in advanced prostate malignancy.

  • Androgen deprivation therapy combinations
  • Metastatic hormone-sensitive prostate cancer
  • Metastatic castration-resistant prostate cancer

The sponsor’s oncology portfolio reflects a strong focus on advanced prostate cancer settings, including both hormone-sensitive and resistant disease states.

About Specializations

Jiangsu Hengrui Pharmaceuticals Co. Ltd. runs clinical trials in conditions such as Prostate cancer, Thrombocytopenia, Hormone-refractory prostate cancer, Prostate cancer metastatic, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

3 clinical trials

Thrombocytopenia

Recruiting

A study to evaluate the effectiveness and safety of efaglomograstim alfa in patients with low blood platelet counts caused by chemotherapy

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Prostate cancer

Not yet recruiting

Study Comparing Rezvilutamide and Bicalutamide with Hormone Therapy for Patients with Advanced Prostate Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Hormone-refractory prostate cancer+2

Not recruiting

Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.